Table 2 |
||
|
Efficacy outcomes (per protocol analysis) on days 14 and 28 |
||
| Day 14 |
AM-L |
AS+AQ |
|
|
||
| ACPR |
100 |
107 |
| ETF |
0 |
0 |
| LCF |
1 |
0 |
| LPF |
2 |
2 |
|
|
||
| Day 28 |
||
|
|
||
| ACPR |
97 |
102 |
| ETF |
0 |
0 |
| LCF |
3 |
1 |
| LPF |
3 |
4 |
|
|
||
|
AM-L = artemether-lumefantrine, AS+AQ = artesunate+amodiaquine Day 28 cure rates are cumulative figures from day 14. ACPR = adequate clinical and parasitological response, ETF = early treatment failure, LCF = late clinical failure, LPF = late parasitological failure |
||
|
Adjei et al. Malaria Journal 2008 7:127 doi:10.1186/1475-2875-7-127 |
||
